Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (Hebei Medical University)
- Development stage
- Unknown
- Lead developer
- The First Hospital of Hebei Medical University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Autologous bone marrow mononuclear cells (BMMCs) is an investigational cell therapy developed by Hebei Medical University for the treatment of diabetic lower limb ischemia. The therapy involves harvesting mononuclear cells from the patient's own bone marrow, typically via iliac crest aspiration, followed by isolation and intramuscular injection into the ischemic regions of the lower limb. This autologous approach is designed to promote therapeutic angiogenesis and improve regional perfusion. The mechanism of action involves the differentiation of transplanted cells into vascular endothelial and smooth muscle cells, alongside the paracrine secretion of pro-angiogenic growth factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which collectively stimulate vascular remodeling and tissue repair in the ischemic limb.
- Other names
- BMMCsautologous bone marrow mononuclear cell transplantationautologous bone marrow mononuclear cells-Hebei Medical University-diabetic lower limb ischemia
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (Hebei Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Hebei Medical University).